Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Runcaciguat modified release - Bayer

Drug Profile

Runcaciguat modified release - Bayer

Alternative Names: BAY 1101042; sGC Activator 1

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bayer
  • Class Amines; Chlorobenzenes; Cyclopropanes; Fluorinated hydrocarbons; Propionic acids; Small molecules; Urologics
  • Mechanism of Action Guanylate cyclase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Diabetic retinopathy; Renal failure

Most Recent Events

  • 29 Apr 2022 Bayer completes the CONCORD phase II trial in Renal failure in Germany, Israel, Slovakia, Ukraine, Sweden, Poland, Italy, Finland, Bulgaria, Spain, Belgium, Austria, Denmark (PO) (NCT04507061)
  • 13 Jul 2021 Bayer prematurely terminates its phase I trial in Renal failure (In Volunteers) in Germany (PO, Tablet) due to changes in the company's development strategy(NCT04820621) (EudraCT2020-005716-22)
  • 07 Apr 2021 Bayer initiates a phase I trial in Renal failure (In Volunteers) in Germany (PO, Tablet) (NCT04820621) (EudraCT2020-005716-22)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top